NASDAQ · NMTR
Healthcare · Biotechnology
$0.07
Down-$0.05 (-42.97%)
Updated Aug 15, 2026, 12:11 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NMTR does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning NMTR.
NMTR research
Company profile and research snapshot.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 18, 2023 | Citigroup | Neutral | — |
| Mar 20, 2023 | Truist Securities | Hold | — |
| Feb 13, 2023 | Citigroup | Neutral | — |
| Nov 10, 2022 | BMO Capital | Outperform | — |
| Sep 27, 2022 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
PennyStocks · Jun 24, 2022
Here's what you need to know about trading penny stocks on June 24th The post What to Know About Buying Penny Stocks on June 24th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research · Nov 18, 2021
The heavy selling pressure might have exhausted for 9 Meters Biopharma, Inc. (NMTR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Benzinga · Oct 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M AnaptysBio, Inc. (NASDAQ: ANAB) announced the signing of an agreement with Sagard Healthcare Royalty Partners to monetize a portion of its future Jemperli royalties and milestones. AnaptysBio said it intends to utilize the proceeds of the transaction towards funding of its wholly owned preclinical and clinical-stage antibody programs. Sagard will pay AnaptysBio $250 million upfront in exchange for royalties payable to AnaptysBio under its GlaxoSmithKline plc (NYSE: GSK) collaboration on annual global net sales of Jemperli below $1 billion starting October 2021. The royalty rate applicable below the $1-billion annual net sales threshold is 8%. Sagard may also receive up to a total of $105 million in potential cash milestones, of which $15 million are subject to certain future Jemperli regulatory filing and approval milestones and up to $90 million are subject to certain commercial sales milestones due prior to Jemperli achieving the $1 billion in annual global net sales threshold. The stock was advancing 3.28% to $29.95 in premarket trading. Moderna's Booster Dose Gets EMA Committee's Backing, Biopharma Strikes Deal To Supply 110M Doses To Africa Moderna, Inc. (NASDAQ: MRNA) said the European Medicines Agency's Committee for Medicinal Products for Human Use has concluded that a booster dose of Spikevax, Moderna's vaccine against COVID-19, at the 50 µg dose level may be considered in people aged 18 years and older at least six months after completion of the primary series. Moderna's booster shot is already authorized in the U.S. Separately, the company announced a new memorandum of understanding to make up to 110 million doses of the Moderna COVID-19 vaccine available to the African Union. The company said it is prepared to deliver the first 15 million doses in the fourth quarter of 2021, 35 million doses in the first quarter of 2022 and up to 60 million doses in second ...
PennyStocks · Oct 13, 2021
Looking for top penny stocks to buy? Check these 3 out for your list The post Top Penny Stocks to Watch? 3 Moving in Today’s Trading Session appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NMTR.
No results
No recent SID articles mention NMTR.
